Autopsy report · NCT03152552

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

“This study terminated prematurely because of slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 10 months before it stopped.
• 125 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Diabetes Mellitus and Heart Failure

Interventions

LIK066; Placebo; Empagliflozin

Participants

125

Sites

106

Countries

Argentina, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Hungary, Ireland, Italy and more

Trials that died the same way

• Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
  “Study terminated due to slower than anticipated enrollment.” (93% match in meaning)
• Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears
  “Slow enrollment resulted in the decision to prematurely terminate the study” (92% match in meaning)
• A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
  “Study has been terminated due to slow enrollment.” (92% match in meaning)
• Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
  “Slow enrollment; study terminated.” (92% match in meaning)
• Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
  “The study was prematurely terminated due to slow enrollment beyond the planned study timelines.” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.